Detalhe da pesquisa
1.
Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial.
Nephrol Dial Transplant
; 38(2): 344-351, 2023 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35212735
2.
Metastatic xanthogranulomatous pyelonephritis managed with immunosuppression.
Nephrology (Carlton)
; 28(9): 506-509, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222079
3.
The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis.
Nephrol Dial Transplant
; 36(4): 649-656, 2021 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31855262
4.
Dietary Phosphate Consumption in Australians With Stages 3b and 4 Chronic Kidney Disease.
J Ren Nutr
; 31(2): 155-163, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32466982
5.
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
J Am Soc Nephrol
; 31(11): 2653-2666, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32917784
6.
Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Am J Nephrol
; 51(3): 201-215, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32023606
7.
Barriers to timely arteriovenous fistula creation: a study of providers and patients.
Am J Kidney Dis
; 57(6): 873-82, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21411202
8.
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
BMJ Open
; 9(2): e024382, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30796122
9.
Temporal distribution of arrhythmic events in chronic kidney disease: Highest incidence in the long interdialytic period.
Heart Rhythm
; 12(10): 2047-55, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26111801
10.
Bradycardia and asystole is the predominant mechanism of sudden cardiac death in patients with chronic kidney disease.
J Am Coll Cardiol
; 65(12): 1263-1265, 2015 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-25814235
11.
Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
Clin J Am Soc Nephrol
; 1(2): 256-62, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17699214